A Phase II Single-arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-small Cell Lung Cancer: Clinical Evaluation of Novel Blood-based Diagnostics
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Acronyms B-F1RST
- Sponsors Genentech
- 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 01 Mar 2017 Planned End Date changed from 1 Jan 2019 to 1 Jun 2020.
- 01 Mar 2017 Planned primary completion date changed from 1 Jan 2019 to 1 Jun 2020.